Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus Chemotherapy as Adjuvant Therapy in Elderly Gastric Cancer
NCT06238167Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by The First Affiliated Hospital of Wenzhou Medical University. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06238167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238167.